VYNE Therapeutics Inc (VYNE)Healthcare | Biotechnology | Stewartsville, United States |
USD
|
Hot Take ↕ | Aug. 22, 2026, 8:46 a.m. UTC
The immediate outlook is severely clouded by a proposed merger with Yarrow Bioscience that has triggered a special dividend and a drastic 1-for-50 reverse stock split, signaling deep capital distress rather than organic growth. While the company currently boasts a massive current ratio of 20.8x due to cash reserves, this liquidity is being rapidly consumed by negative operating cash flows of roughly $25.7 million and free cash flow burn of $20.4 million, indicating an unsustainable financial trajectory. The business fundamentals are deteriorating sharply, evidenced by a 57.4% contraction in revenue and negative returns on both assets and equity, suggesting the core operations are failing to generate value. Although the upcoming special dividend offers a temporary yield, it acts more as a return of capital to bridge a funding gap than a sustainable income stream, leaving the long-term investment case fundamentally broken. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-07-22 |
| Last Dividend Date | 2026-07-22 |
| Revenue per Share | 0.53 |
| Market Cap | 19,069,540 |
| Forward P/E | -0.35 |
| Beta | 2.01 |
| Website | https://vynetherapeutics.com |
| Date | Dividend | Yield % |
|---|---|---|
| 2026-07-22 | 20.121 | NaN |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5263014 |
| Address1 | P.O. BOX 125 |
| All Time High | 143,495.98 |
| All Time Low | 14.025 |
| Ask | 31.36 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 47,289 |
| Average Volume | 17,632 |
| Average Volume10Days | 47,289 |
| Beta | 2.006 |
| Bid | 20.35 |
| Bid Size | 200 |
| Book Value | 36.934 |
| City | Stewartsville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 28.56 |
| Current Ratio | 20.865 |
| Date Short Interest | 1,784,073,600 |
| Day High | 28.56 |
| Day Low | 23.37 |
| Ebitda | -24,345,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.241 |
| Enterprise To Revenue | -12.945 |
| Enterprise Value | -5,876,852 |
| Ex Dividend Date | 1,784,678,400 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 34.0342 |
| Fifty Two Week High | 46.95 |
| Fifty Two Week Low | 14.025 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 613,692 |
| Forward Eps | -82.5 |
| Forward P E | -0.3461818 |
| Free Cashflow | -20,400,000 |
| Full Time Employees | 10 |
| Fullday Price | 28.56 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 454,000 |
| Held Percent Insiders | 0.17934999 |
| Held Percent Institutions | 0.39619 |
| Implied Shares Outstanding | 667,701 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Dividend Date | 1,784,678,400 |
| Last Dividend Value | 20.121 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,785,110,400 |
| Last Split Factor | 1:50 |
| Long Business Summary | VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey. |
| Long Name | VYNE Therapeutics Inc |
| Market Cap | 19,069,540 |
| Max Age | 86,400 |
| Message Board Id | finmb_6511914 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -21,718,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Open | 25.5 |
| Operating Cashflow | -25,744,000 |
| Operating Margins | -44.37209 |
| Payout Ratio | 0.0 |
| Phone | 800 775 7936 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 0.77327126 |
| Price To Sales Trailing12 Months | 42.00339 |
| Profit Margins | 0.0 |
| Quick Ratio | 20.168 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 28.56 |
| Regular Market Day Low | 23.37 |
| Regular Market Open | 25.5 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 93,256 |
| Return On Assets | -0.37013 |
| Return On Equity | -0.63162 |
| Revenue Growth | -0.574 |
| Revenue Per Share | 0.53 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 667,701 |
| Shares Percent Shares Out | 0.0055 |
| Shares Short | 3,679 |
| Shares Short Previous Month Date | 1,781,481,600 |
| Shares Short Prior Month | 2,201 |
| Short Name | VYNE Therapeutics Inc. |
| Short Percent Of Float | 0.0056 |
| Short Ratio | 0.15 |
| State | NJ |
| Symbol | VYNE |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 24,928,000 |
| Total Cash Per Share | 37.37 |
| Total Debt | 0 |
| Total Revenue | 454,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -27.58 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 28.596624 |
| Underlying Symbol | VYNE |
| Uuid | 6b428866-1c06-3cdf-aea1-c192e2cb997e |
| Volume | 93,256 |
| Website | https://vynetherapeutics.com |
| Zip | 8,886 |